Mark Delworth, MD
Urology · Blue Ash, OHNPI 1275579856
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (27.4%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Intuitive Surgical at 40.1% of the total. Reporting peaked in 2019 at $24,616 and has fallen 74.6% since, to $6,260 in 2025. Among urology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 672 payments — averaging $112.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$30K
- Astellas Pharma US Inc$16K
- Johnson & Johnson$5K
- Medtronic$5K
- Janssen Scientific Affairs, LLC$5K
- Boston Scientific$3K
- plus $11K from 40 others
What the payments were for
- Consulting fees$12,55617%
- Speaking & faculty fees$14,11519%
- Travel & lodging$10,62414%
- Food & beverage$17,76123%
- Education$20,75227%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$29,140
- XTANDI$11,293
- Erleada$4,854
- AMS 700$653
- GENERAL ERECTILE DYSFUNCTION$651
- Signia$380
- CVAC Aspiration System$264
- Xofigo$258
- LYNPARZA$244
- PROVENGE$150
- Nubeqa$147
- AKEEGA$147
- Balversa$142
- LithoVue$132
- Axonics r-SNM System$127
- Pipeline$124
- UroLift$123
- AMS$120
- BIOPROTECT BALLOON IMPLANT SYSTEM$117
- AIRSEAL$109
How this compares
$75,822 in reported general payments places this provider in the 95th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 342 | $4,531,646 |
| ErleadaApalutamide | 77 | $1,218,480 |
| NubeqaDarolutamide | 41 | $552,503 |
| OrgovyxRelugolix | 157 | $419,080 |
| TalzennaTalazoparib Tosylate | 15 | $265,940 |
| Abiraterone Acetate | 231 | $208,024 |
| ZytigaAbiraterone Acetate | 14 | $154,261 |
| XgevaDenosumab | 33 | $104,012 |
| Lupron DepotLeuprolide Acetate | 18 | $99,955 |
| MyrbetriqMirabegron | 103 | $75,311 |
| EligardLeuprolide Acetate | 29 | $41,619 |
| ProliaDenosumab | 18 | $29,684 |
| GemtesaVibegron | 19 | $19,663 |
| Tamsulosin Hcl | 778 | $10,534 |
| Testosterone | 32 | $6,404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $16,181 | $4,606,958445 claims |
| Johnson & JohnsonErleada, Zytiga | $5,202 | $1,372,74091 claims |
| BayerNubeqa | $938 | $552,50341 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $665 | $438,743176 claims |
| PfizerTalzenna | $432 | $265,94015 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $4,642 | $208,024231 claims |
| AmgenXgeva, Prolia | $53 | $133,69551 claims |
| AbbVieLupron Depot | $509 | $99,95518 claims |
| Tolmar Pharmaceuticals, Inc.Eligard | $106 | $41,61929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 485 urology providers in Ohio.
Other urology in Blue Ash
- Gary KirshBlue Ash$73K
- Lawrence GervasiMiddleburg Heights$1.1M
- Howard GoldmanCleveland$721K
- Ronney AbazaWorthington$374K
- Sriharan SivalingamCleveland$276K
- Sandip VasavadaCleveland$263K
- Jihad KaoukCleveland$234K
- Benjamin MartinGahanna$205K
- Ruben OlivaresCleveland$184K
- Abhinav SidanaCincinnati$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.